Quote:
Yes, I meant the certificate of veterinary inspection, sorry about that
Actually, from what I've learned Marek's vaccs are not recommended for small back yard flocks, because of the side affects from the Vacc. and as Cindy said for a back yard flock it isn't cost effective.
That why i don't give the vac to mine, they eat med chick starter for that, if you put an unvac chick with a vac chick, well i went threw that and that's when i dug deeper into it, the vac is actually and virus so the unvac chick can get sick, and the vac chicks there immune system is way weaker than normal for about 2 weeks .
Medicated chick starter does not prevent or treat for Mareks. It's primary intention is prevention of coccidiosis.
From the Merck Vet Manual (http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/203602.htm):
Yes, I meant the certificate of veterinary inspection, sorry about that
Actually, from what I've learned Marek's vaccs are not recommended for small back yard flocks, because of the side affects from the Vacc. and as Cindy said for a back yard flock it isn't cost effective.
That why i don't give the vac to mine, they eat med chick starter for that, if you put an unvac chick with a vac chick, well i went threw that and that's when i dug deeper into it, the vac is actually and virus so the unvac chick can get sick, and the vac chicks there immune system is way weaker than normal for about 2 weeks .
Medicated chick starter does not prevent or treat for Mareks. It's primary intention is prevention of coccidiosis.
From the Merck Vet Manual (http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/203602.htm):
Control:
Vaccination is the central strategy for the prevention and control of Mareks disease. The efficacy of vaccines can be improved, however, by strict sanitation to reduce or delay exposure and by breeding for genetic resistance. Probably the most widely used vaccine consists of turkey herpesvirus. Bivalent vaccines consisting of turkey herpesvirus and either the SB-1 or 301B/1 strains of serotype 2 Mareks disease virus have been used to provide additional protection against challenge with virulent serotype 1 isolates. Several attenuated serotype 1 Mareks disease vaccines are also available; of these, the CV1988/Rispens strains appears particularly effective. A synergistic effect on protection, noted mainly between serotype 2 and 3 strains, has prompted the empirical use of other virus mixtures. Because vaccines are administered at hatching and require 1-2 wk to produce an effective immunity, exposure of chickens to virus should be minimized during the first few days after hatching. Vaccines are also effective when administered to embryos at the 18th day of incubation. In ovo vaccination is now performed by automated technology and is widely used for vaccination of commercial broiler chickens, mainly because of reduced labor costs and greater precision of vaccine administration. Proper handling of vaccine during thawing and reconstitution is crucial to ensure that adequate doses are administered. Cell-associated vaccines are generally more effective than cell-free vaccines because they are neutralized less by maternal antibodies. Under typical conditions, vaccine efficacy is usually >90%. Since the advent of vaccination, losses from Mareks disease have been reduced dramatically in broiler and layer flocks. However, disease may become a serious problem in individual flocks or in selected geographic areas (eg, the Delmarva broiler industry). Of the many causes proposed for these excessive losses, early exposure to very virulent virus strains appears to be among the most important. Using fowlpox virus and herpesvirus of turkeys as vectors, experimental recombinant vaccines have been shown to be effective against challenge with virulent Mareks disease virus.
Vaccination is the central strategy for the prevention and control of Mareks disease. The efficacy of vaccines can be improved, however, by strict sanitation to reduce or delay exposure and by breeding for genetic resistance. Probably the most widely used vaccine consists of turkey herpesvirus. Bivalent vaccines consisting of turkey herpesvirus and either the SB-1 or 301B/1 strains of serotype 2 Mareks disease virus have been used to provide additional protection against challenge with virulent serotype 1 isolates. Several attenuated serotype 1 Mareks disease vaccines are also available; of these, the CV1988/Rispens strains appears particularly effective. A synergistic effect on protection, noted mainly between serotype 2 and 3 strains, has prompted the empirical use of other virus mixtures. Because vaccines are administered at hatching and require 1-2 wk to produce an effective immunity, exposure of chickens to virus should be minimized during the first few days after hatching. Vaccines are also effective when administered to embryos at the 18th day of incubation. In ovo vaccination is now performed by automated technology and is widely used for vaccination of commercial broiler chickens, mainly because of reduced labor costs and greater precision of vaccine administration. Proper handling of vaccine during thawing and reconstitution is crucial to ensure that adequate doses are administered. Cell-associated vaccines are generally more effective than cell-free vaccines because they are neutralized less by maternal antibodies. Under typical conditions, vaccine efficacy is usually >90%. Since the advent of vaccination, losses from Mareks disease have been reduced dramatically in broiler and layer flocks. However, disease may become a serious problem in individual flocks or in selected geographic areas (eg, the Delmarva broiler industry). Of the many causes proposed for these excessive losses, early exposure to very virulent virus strains appears to be among the most important. Using fowlpox virus and herpesvirus of turkeys as vectors, experimental recombinant vaccines have been shown to be effective against challenge with virulent Mareks disease virus.
